Tag Archives: BRAF mutation

November, 2016

9 November
Array BioPharma, Pierre-Fabre Drug Combo Meets Main Goal in Late-Stage Melanoma Study

BOULDER, Colo., and CASTRES, France, Nov. 9, 2016 /PRNewswire/ — Array BioPharma (Nasdaq: ARRY) and Pierre Fabre today jointly announced new results from the pivotal Phase 3 COLUMBUS trial of binimetinib plus encorafenib (bini/enco) treatment in BRAF-mutant melanoma patients at the Society for Melanoma Research Annual Congress. The study met its primary …
Share

6 October
Exelixis Announces Positive Results for its Late-Stage Melanoma Trial

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Oct. 6, 2015– Exelixis, Inc.(NASDAQ:EXEL) today announced positive overall survival (OS) results from coBRIM, the phase 3 pivotal trial evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma carrying a BRAF V600 …
Share